These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33230550)

  • 1. Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children.
    Tagbo BN; Verma H; Mahmud ZM; Ernest K; Nnani RO; Chukwubike C; Craig KT; Hamisu A; Weldon WC; Oberste SM; Jeyaseelan V; Braka F; Mkanda P; Esangbedo D; Olowu A; Nwaze E; Sutter RW
    J Infect Dis; 2022 Aug; 226(2):299-307. PubMed ID: 33230550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
    Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
    Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.
    Snider CJ; Zaman K; Estivariz CF; Aziz AB; Yunus M; Haque W; Hendley WS; Weldon WC; Oberste MS; Pallansch MA; Wassilak SGF; Anand A
    Vaccine; 2024 Sep; 42(22):126216. PubMed ID: 39146859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
    Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
    Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of Different Routine Poliovirus Vaccination Schedules: A Randomized, Controlled Trial in Karachi, Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Steven Oberste M; Zaidi SS; Alam MM; Quadri F; Sutter RW; Zaidi AKM
    J Infect Dis; 2018 Jan; 217(3):443-450. PubMed ID: 29126173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
    Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
    Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
    Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
    Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
    Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
    Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
    Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
    Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
    Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.
    John J; Giri S; Karthikeyan AS; Iturriza-Gomara M; Muliyil J; Abraham A; Grassly NC; Kang G
    Lancet; 2014 Oct; 384(9953):1505-12. PubMed ID: 25018120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India.
    Mohanty L; John TJ; Pawar SD; Ramanan PV; Agarkhedkar S; Haldar P
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of sequential poliovirus vaccination schedules with different strains of poliomyelitis vaccines in Chongqing, China: a cross-sectional survey.
    Xu J; Wang Q; Kuang S; Rong R; Zhang Y; Fu X; Tang W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2125-2131. PubMed ID: 33759702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
    Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
    Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial.
    Zaman K; Kovacs SD; Vanderende K; Aziz A; Yunus M; Khan S; Snider CJ; An Q; Estivariz CF; Oberste MS; Pallansch MA; Anand A
    Vaccine; 2021 Sep; 39(40):5814-5821. PubMed ID: 34481702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.